(9R)-9-phenylphosphindolo[2,3-b]pyridine 9-oxide
SD118 was previously under investigation in Japan for a different indication and now, following re-profiling and evaluation in experimental animal models, has demonstrated its potential as a new oral therapy for neuropathic pain.